[1]杨秀萍.格列净联合常规抗心衰药物治疗射血分数下降心衰患者的疗效[J].医学信息,2024,37(20):84-87.[doi:10.3969/j.issn.1006-1959.2024.20.015]
　YANG Xiuping.Efficacy of Dapagliflozin Combined with Conventional Anti-heart Failure Drugs in the Treatment of Heart Failure Patients with Reduced Ejection Fraction[J].Journal of Medical Information,2024,37(20):84-87.[doi:10.3969/j.issn.1006-1959.2024.20.015]
点击复制

格列净联合常规抗心衰药物治疗射血分数下降心衰患者的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年20期
页码:
84-87
栏目:
论著
出版日期:
2024-10-15

文章信息/Info

Title:
Efficacy of Dapagliflozin Combined with Conventional Anti-heart Failure Drugs in the Treatment of Heart Failure Patients with Reduced Ejection Fraction
文章编号:
1006-1959（2024）20-0084-04
作者:
杨秀萍
铅山县人民医院内四科，江西 铅山 334500
Author(s):
YANG Xiuping
The Fourth Department of Internal Medicine,Yanshan County People ’s Hospital,Yanshan 334500,Jiangxi,China
关键词:
射血分数下降性心衰; 达格列净; 左室射血分数; 生活质量
Keywords:
Heart failure with reduced ejection fraction; Dapagliflozin; Left ventricular ejection fraction; Quality of life
分类号:
R541
DOI:
10.3969/j.issn.1006-1959.2024.20.015
摘要:
目的 研究达格列净联合常规抗心衰药物治疗射血分数下降心衰（HFrEF）患者的临床疗效。方法 以2021年1月-2023年3月铅山县人民医院收治的52例HFrEF患者为研究对象，经随机数字表法分为对照组（26例）与观察组（26例）。对照组行常规抗心衰药物治疗，观察组在其基础上联合达格列净治疗，比较两组临床疗效、心功能[左室射血分数（LVEF）、左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）]、心力衰竭症状状态问卷（SSQ-HF）、6 min步行距离（6MWD）、明尼苏达心力衰竭生活质量（MLHFQ）评分、再住院率、主要不良心血管事件（MACE）发生率。结果 观察组治疗总有效率为96.15%，高于对照组的76.92%（P＜0.05）；两组治疗后LVEF大于治疗前，LVESD、LVEDD小于治疗前，且观察组LVEF大于对照组，LVESD、LVEDD小于对照组（P＜0.05）；两组治疗后SSQ-HF评分低于治疗前，6MWD大于治疗前，且观察组治疗后SSQ-HF评分低于对照组，6MWD大于对照组（P＜0.05）；两组治疗后MLHFQ评分（身体领域、情绪领域、其他领域）低于治疗前，且观察组治疗后MLHFQ评分（身体领域、情绪领域、其他领域）低于对照组（P＜0.05）；观察组再住院率、MACE发生率小于对照组（P＜0.05）。结论 达格列净联合常规抗心衰药物治疗HFrEF效果肯定，可改善患者心功能，缓解心衰症状，降低患者再住院率及MACE风险，进而提升生活质量。
Abstract:
Objective To study the clinical efficacy of dapagliflozin combined with conventional anti-heart failure drugs in the treatment of patients with heart failure with reduced ejection fraction (HFrEF).Methods A total of 52 patients with HFrEF admitted to Yanshan County People’s Hospital from January 2021 to March 2023 were divided into control group (26 patients) and observation group (26 patients) by random number table method. The control group was treated with conventional anti-heart failure drugs, and the observation group was treated with dapagliflozin on the basis of the control group. The clinical efficacy, cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD)], the Symptom Status Questionnaire-Heart Failure (SSQ-HF), 6-minute walking distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, rehospitalization rate, and incidence of major adverse cardiovascular events (MACE) were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.15%, which was higher than 76.92% in the control group (P<0.05). After treatment, LVEF in the two groups was larger than that before treatment, LVESD and LVEDD were smaller than those before treatment, and LVEF in the observation group was larger than that in the control group, LVESD and LVEDD were smaller than those in the control group (P<0.05). After treatment, the SSQ-HF score of the two groups was lower than that before treatment, and the 6MWD was higher than that before treatment. After treatment, the SSQ-HF score of the observation group was lower than that of the control group, and the 6MWD was higher than that of the control group (P<0.05). After treatment, the MLHFQ scores (physical field, emotional field, other fields) of the two groups were lower than those before treatment, and the MLHFQ scores (physical field, emotional field, other fields) of the observation group were lower than those of the control group (P<0.05). The rehospitalization rate and the incidence of MACE in the observation group were lower than those in the control group (P<0.05).Conclusion Dapagliflozin combined with conventional anti-heart failure drugs is effective in the treatment of HFrEF, which can improve the cardiac function of patients, relieve the symptoms of heart failure, reduce the rehospitalization rate and MACE risk of patients, and thus improve the quality of life.

参考文献/References:

[1]许琳慧,王万虹,张义,等.达格列净治疗2型糖尿病合并射血分数轻度下降心力衰竭患者的临床疗效[J].海南医学院学报,2023,29(9):681-687.[2]王艳飞,马娟,杨云巧.沙库巴曲缬沙坦对射血分数降低合并低血压心衰患者的临床疗效及安全性的影响[J].昆明医科大学学报,2022,43(11):136-140.[3]范海,王岳松,王学忠,等.重组人脑利钠肽联用达格列净对射血分数降低的心力衰竭患者预后的影响[J].中国新药与临床杂志,2023,42(2):141-144.[4]沈祎玲,祁春梅.达格列净联合美托洛尔治疗2型糖尿病合并慢性心力衰竭的临床效果[J].中国医药,2022,17(12):1804-1808.[5]倪润泽,冯俊.达格列净治疗老年射血分数降低性心力衰竭患者的疗效及安全性[J].岭南心血管病杂志,2023,29(1):68-73.[6]刘荣志,林子祥,陈海晋,等.达格列净对射血分数降低的心力衰竭患者的效果观察[J].实用临床医药杂志,2023,27(3):35-39,45.[7]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[8]张虎,谭伟,阮佩,等.达格列净片联合麝香保心丸治疗射血分数降低心力衰竭急性发作期的临床疗效观察[J].中国实验方剂学杂志,2022,28(17):98-105.[9]刘姗姗,赵璨,罗力亚.达格列净治疗老年2型糖尿病并心力衰竭患者的临床疗效及其对心功能的影响[J].实用心脑肺血管病杂志,2022,30(3):107-111.[10]王赛男,陈列.三种左心室射血分数心力衰竭患者的临床特点比较以及近中期预后探讨[J].解放军预防医学杂志,2019,37(4):61-62.[11]张邻川,夏成功,唐文明,等.达格列净片治疗2型糖尿病合并慢性心力衰竭患者的临床研究[J].中国临床药理学杂志,2021,37(19):2573-2576,2595.[12]杨攀,张琼,王学影.达格列净治疗射血分数降低心衰患者的疗效观察[J].广西医科大学学报,2021,38(7):1436-1441.[13]贺红祥,李贵民,张文魁.沙库巴曲缬沙坦联合达格列净治疗2型糖尿病合并心力衰竭患者的临床对照研究[J].实用心脑肺血管病杂志,2021,29(6):99-104.[14]雒番阳,郝瑞军,郭亚妮.沙库巴曲缬沙坦治疗高龄射血分数降低心衰患者的临床疗效及安全性[J].贵州医药,2020,44(4):618-620.[15]刘翩,周小翠,汪涛.达格列净片治疗2型糖尿病合并心力衰竭患者的临床研究[J].中国临床药理学杂志,2021,37(3):227-230.[16]缪雄,陆洋,颜永进,等.达格列净治疗老年心力衰竭的效果及对血清ST2、NT-proBNP水平的影响[J].实用老年医学,2021,35(2):191-193.[17]马明,谢华宁,张军茹.达格列净治疗2型糖尿病合并慢性心力衰竭临床疗效观察[J].陕西医学杂志,2021,50(1):93-95,99.[18]陈方圆,田刚,白晓君,等.沙库巴曲缬沙坦对射血分数降低心衰患者心脏重构及心功能的影响[J].西部医学,2020,32(10):1492-1495,1499.[19]羡微微,刘桂清.沙库巴曲缬沙坦对射血分数降低性心衰患者血浆去甲肾上腺素和血清心肌肌钙蛋白I水平的影响研究[J].陕西医学杂志,2020,49(10):1306-1309.[20]杨光全,展庆垒,吴付轩.达格列净对慢性心力衰竭合并2型糖尿病患者左心室舒张功能的影响[J].中国循证心血管医学杂志,2019,11(9):1118-1120,1124.[21]柴俊兵,吕钢,刘华,等.达格列净治疗射血分数降低心力衰竭的临床效果观察[J].中华保健医学杂志,2022,24(5):373-375.

相似文献/References:

[1]孙寿广.达格列净治疗2型糖尿病的研究进展[J].医学信息,2018,31(19):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
　SUN Shou-guang.Progress in the Study of Dapagliflozin in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2018,31(20):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
[2]董 健.达格列净治疗2型糖尿病的疗效及其对体质指数的影响[J].医学信息,2020,33(07):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
　DONG Jian.The Therapeutic Effect of Dapagliflozin on Type 2 Diabetes and Its Influence on Body Mass Index[J].Journal of Medical Information,2020,33(20):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
[3]樊小莉.达格列净治疗老年糖尿病的临床疗效及其对肾功能影响[J].医学信息,2020,33(13):158.[doi:10.3969/j.issn.1006-1959.2020.13.048]
　FAN Xiao-li.The Clinical Efficacy of Dapagliflozin in the Treatment of Senile Diabetes and Its Influence on Renal Function[J].Journal of Medical Information,2020,33(20):158.[doi:10.3969/j.issn.1006-1959.2020.13.048]
[4]郑黄生,周炳凤.钠-葡萄糖协同转运蛋白-2抑制剂治疗射血分数降低心力衰竭的疗效及预后分析[J].医学信息,2021,34(10):92.[doi:10.3969/j.issn.1006-1959.2021.10.025]
　ZHENG Huang-sheng,ZHOU Bing-feng.Efficacy and Prognosis of Sodium-glucose Cotransporter-2 Inhibitor in Treatment of Heart Failure with Lower Ejection Fraction[J].Journal of Medical Information,2021,34(20):92.[doi:10.3969/j.issn.1006-1959.2021.10.025]
[5]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(20):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[6]廖 萌,淦作梅.达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响[J].医学信息,2024,37(13):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
　Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type Diabetes Mellitus.Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(20):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
[7]黄 斌,谭洁芬,刘燕萍,等.达格列净联合利格列汀在肥胖2型糖尿病患者中的效果及安全性[J].医学信息,2024,37(17):124.[doi:10.3969/j.issn.1006-1959.2024.17.026]
　HUANG Bin,TAN Jie-fen,LIU Yan-ping,et al.Effect and Safety of Dapagliflozin Combined with Linagliptin in Obese Patientswith Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(20):124.[doi:10.3969/j.issn.1006-1959.2024.17.026]
[8]刘 璇,陈珍珍.达格列净联合二甲双胍在2型糖尿病治疗中的临床疗效[J].医学信息,2025,38(02):116.[doi:10.3969/j.issn.1006-1959.2025.02.021]
　LIU Xuan,CHEN Zhenzhen.Clinical Efficacy of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2025,38(20):116.[doi:10.3969/j.issn.1006-1959.2025.02.021]

更新日期/Last Update: 1900-01-01